Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-10-05 pm EDT
2.560 USD   -3.76%
09/28Lyell Immunopharma Names Rahsaan W. Thompson Chief Legal Officer
MT
09/20Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/12Gritstone Bio Says Cancer Immunotherapies Showed 'Early Evidence of Efficacy' in Phase 1/2 Study; Shares Rise
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08/17/2022 | 07:01am EDT

EMERYVILLE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted eight employees nonqualified stock options to purchase an aggregate of 239,100 shares of its common stock with an exercise price of $3.40, which is equal to the closing price of Gritstone’s common stock on August 10, 2022, the date of the grant. These stock options are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees’ date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees’ continued employment with Gritstone on such vesting dates. The stock options are subject to the terms and conditions of Gritstone’s 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.

About Gritstone
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; the advancements in Gritstone’s ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ clinical stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gritstone in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on August 4, 2022 and Gritstone’s future reports to be filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof. Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corp Comms
Gritstone bio, Inc.
ir@gritstone.com

Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com


Primary Logo

Source: Gritstone bio

2022 GlobeNewswire, Inc., source Press Releases

All news about GRITSTONE BIO, INC.
09/28Lyell Immunopharma Names Rahsaan W. Thompson Chief Legal Officer
MT
09/20Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/12Gritstone Bio Says Cancer Immunotherapies Showed 'Early Evidence of Efficacy' in Phase ..
MT
09/12Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Trea..
AQ
09/12Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Pat..
CI
09/01Gritstone to Participate in Two Upcoming Investor Conferences
AQ
08/22Goldman Sachs Downgrades Gritstone bio to Sell From Neutral; Price Target is $2
MT
08/17Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/15Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of GRANI..
AQ
08/15Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study..
CI
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 19,2 M - -
Net income 2022 -123 M - -
Net cash 2022 23,0 M - -
P/E ratio 2022 -1,66x
Yield 2022 -
Capitalization 187 M 187 M -
EV / Sales 2022 8,53x
EV / Sales 2023 13,6x
Nbr of Employees 193
Free-Float 97,0%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 2,56 $
Average target price 11,33 $
Spread / Average Target 343%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Executive VP & Head-Research & Development
Erin E. Jones Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-80.09%194
CSL LIMITED-1.14%90 052
SAMSUNG BIOLOGICS CO.,LTD.-10.63%40 706
BIOGEN INC.9.07%38 810
WUXI BIOLOGICS (CAYMAN) INC.-47.81%26 225
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 439